덱스컴 (DXCM)

Shares of DexCom, Inc. (DXCM) dropped by 7.32% from $85.21 to $78.97 in the trading on Wednesday, October 11, 2023. The reason why DXCM stock down is due to a competitor's successful kidney disease prevention drug. However, the stock drop was not exclusive to DexCom, as some other dialysis companies like DaVita and Baxter International also suffered losses. This market turbulence was triggered by Novo Nordisk's early termination of a phase 3 trial for Ozempic (semaglutide), which showed remarkable effectiveness in slowing kidney disease progression in type 2 diabetes and chronic kidney disease patients, potentially disrupting the need for dialysis. This setback compounded DexCom's existing struggles, now that the announcement by Novo Nordisk hurts kidney dialysis provider.

DexCom's stock fell 5.91% as investors retreated from the earlier bullish trend.

https://www.benzinga.com/news/23/07/33478042/why-apellis-pharmaceuticals-shares-are-trading-lower-by-around-19-here-are-other-stocks-moving-in-mo